Dr Stephanie Gibbs


Clinical oncologist

Special clinical interest in clinical oncology.

Dr Gibbs trained in Oncology at the Middlesex, Mount Vernon, Royal London & St Bartholomews’ Hospitals. She was appointed as a consultant in 1998 & since then has specialised in prostate, bladder, breast, colorectal & ovarian cancer treatment. She is clinical lead for oncology research at Queens Hospital.

Clinical Oncology

NHS Hospital / current post(s)
Queens Hospital, Romford. Consultant Oncologist

Year Qualified

Clinical Interests
Urological Cancer

Research Interests
Prostate & bladder cancer

Professional Memberships
Fellow of Royal College of Radiology, Royal Society of Medicine, British Medical Association, British Uro-oncology Group

Awards Received
Honorary Clinical Senior Lecturer
Queen Mary University of London

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
M R Sydes et al MRC Clinical Trials Unit at UCL, London
Annals of Oncology, Volume 29, Issue 5, 1 May 2018, Pages 1235–1248, https://doi.org/10.1093/annonc/mdy072
Presentation at ESTRO 37 conference Barcelona April 2018
Clinical outcomes of the first RCT of adaptive radiotherapy in bladder cancer (HYBRID CRUK/12/055)
R Huddart at al
Poster presentation at GU ASCO San Francisco February 2018
Results of POUT – A phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer
A Birtle et al
Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): long-term survival, quality-adjusted survival and cost-effectiveness analysis
Matthew Sydes et al
European Urology Oncology May 2018